Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP

doi:10.1182/blood.2019004753

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

Identifier:nobleid.org/w1/20260526/6E56ADAF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6E56ADAF.svg?ark=w1%2F20260526%2F6E56ADAF)](https://nobleid.org/work/w1/20260526/6E56ADAF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

Identifier:nobleid.org/w1/20260526/6E56ADAF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6E56ADAF.svg?ark=w1%2F20260526%2F6E56ADAF)](https://nobleid.org/work/w1/20260526/6E56ADAF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work